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Abstract
Background: Low-value clinical practices are common in healthcare, yet the optimal approach to de-adopting
these practices is unknown. The objective of this study was to systematically review the literature on de-adoption,
document current terminology and frameworks, map the literature to a proposed framework, identify gaps in our
understanding of de-adoption, and identify opportunities for additional research.
Methods: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic
Reviews, the Cochrane Database of Abstracts and Reviews of Effects, and CINAHL Plus were searched from 1 January
1990 to 5 March 2014. Additional citations were identified from bibliographies of included citations, relevant websites,
the PubMed ‘related articles’ function, and contacting experts in implementation science. English-language citations
that referred to de-adoption of clinical practices in adults with medical, surgical, or psychiatric illnesses were included.
Citation selection and data extraction were performed independently and in duplicate.
Results: From 26,608 citations, 109 were included in the final review. Most citations (65 %) were original research with
the majority (59 %) published since 2010. There were 43 unique terms referring to the process of de-adoption—the
most frequently cited was “disinvest” (39 % of citations). The focus of most citations was evaluating the outcomes of
de-adoption (50 %), followed by identifying low-value practices (47 %), and/or facilitating de-adoption (40 %). The
prevalence of low-value practices ranged from 16 % to 46 %, with two studies each identifying more than 100
low-value practices. Most articles cited randomized clinical trials (41 %) that demonstrate harm (73 %) and/or lack
of efficacy (63 %) as the reason to de-adopt an existing clinical practice. Eleven citations described 13 frameworks
to guide the de-adoption process, from which we developed a model for facilitating de-adoption. Active change
interventions were associated with the greatest likelihood of de-adoption.
Conclusions: This review identified a large body of literature that describes current approaches and challenges to
de-adoption of low-value clinical practices. Additional research is needed to determine an ideal strategy for identifying
low-value practices, and facilitating and sustaining de-adoption. In the meantime, this study proposes a model that
providers and decision-makers can use to guide efforts to de-adopt ineffective and harmful practices.
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Background
Clinical practice evolves in response to scientific evidence
through a process of discovery (novel practice introduced
into clinical practice, e.g., systemic thrombolysis for acute
ST-elevation myocardial infarction (STEMI) [1]), replace-
ment (newer, more effective practice supplants current
practice, e.g. tenecteplase superior to alteplase among pa-
tients with STEMI [2]), or reversal (current practice shown
to be ineffective or harmful, e.g., suppression of ventricular
ectopy after a myocardial infarction using encainide, flecai-
nide, or moricizine [3]) [4]. Discovery and replacement
introduce novel, beneficial therapies into clinical practice,
while reversal implies that patients receive no benefit and
may be at risk of harm [5]. The adoption of clinical prac-
tices that are later de-adopted imposes substantial ineffi-
ciencies on the healthcare system wherein resources that
could have been dedicated to other purposes are in-
stead devoted to a practice that was ineffective or
harmful (e.g., self-monitoring of blood glucose in pa-
tients with type 2 diabetes mellitus managed without
insulin) [6].
Practice reversal is common [5, 7, 8]. A recent review
of articles published in a major general medical journal
between 2001 and 2010 found that 27 % of original arti-
cles re-examined the efficacy of an established practice,
among which 40 % found evidence for practice reversal
[7]. In another review, commissioned by the Australian
government’s Comprehensive Management Framework
for managing their Medical Benefits Schedule, Elshaug
and colleagues triangulated data from searches of the
peer-reviewed literature, targeted health technology da-
tabases, and opportunistic sampling of stakeholder
groups to identify 156 potentially unsafe and/or ineffect-
ive practices [8].
Medical reversal may be an unavoidable consequence of
evidence-based medicine and/or early technology adop-
tion; however, it is important that its incidence remain
low given the threat that it poses to providing high-quality
healthcare. It is equally important that any intervention
with evidence for medical reversal be rapidly de-adopted.
We were unable to identify any knowledge synthesis that
systematically examined the de-adoption of established
clinical practices. We conducted this scoping review to de-
scribe the literature on de-adoption, document current
terminology and frameworks, map the literature to a pro-
posed conceptual framework (Table 1), identify gaps in
the understanding of this important concept, and identify
opportunities for more detailed evidence syntheses and/or
empirical research.
Methods
We developed a conceptual framework for this work that
employed the key features of Everett Rogers’ Innovation-
Decision model to conceptualize de-adoption (Table 1)
[9]. De-adoption was defined as the discontinuation of a
clinical practice after it was previously adopted [9]. We
followed established scoping review methodology [10, 11],
and used the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines to
report the methods and results [12].
Eligibility criteria
We included English-language citations that referred to
the de-adoption of any clinical practice in adults (mean
age ≥ 18 years) with medical, surgical, or psychiatric ill-
nesses. All original and non-original quantitative and
qualitative research citations were eligible; however, we
excluded citations that exclusively described the
adoption of practices or appropriateness of resource use
(e.g., selected use of antimicrobials, appropriate use of
surgical procedures, appropriate use of lumbar spine
radiography among patients with lower back pain). Al-
though de-adoption is a component within the larger
issue of resource optimization, the “appropriateness” of
a clinical practice embodies more than simply discon-
tinuing its use. Therefore, we excluded citations primar-
ily focused on clinical practice appropriateness.
Search strategy and data sources
With the help of a medical librarian, we searched the
following electronic databases from 1 January 1990 to
5 March 2014: Ovid MEDLINE, Ovid EMBASE, the
Cochrane Central Register of Controlled Trials
(CENTRAL), the Cochrane Database of Systematic
Reviews, the Cochrane Database of Abstracts and
Reviews of Effects, and CINAHL Plus. Pilot searches
in MEDLINE suggested that none of the currently
available Medical Subject Heading (MeSH) terms were
specific to articles reporting de-adoption. Therefore,
the MEDLINE search was confined to use of text
words that included combinations and synonyms of
de-adoption and healthcare technologies (Additional
file 1: Appendix). Search terms were combined using the
appropriate Boolean logic, and included wildcards to ac-
count for plural words and variations in spelling. The
search strategy included similar combinations of terms
within the other databases. To ensure reproducibility, the
MEDLINE search strategy was peer reviewed by a second
medical librarian using the Peer Review of Electronic
Search Strategies (PRESS) checklist [13].
To increase the sensitivity of the search strategy, we also
searched the gray literature according to recommendations
from the Canadian Agency for Drugs and Technologies in
Health [14]. Relevant websites included The Canadian
Agency for Drugs and Technologies in Health, Program
for Assessment of Technology in Health, Australian
Government Medical Services Advisory Committee,
Austrian Institute of Technology Assessment, National
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Institute for Health and Care Excellence, Agency for
Healthcare Research and Quality, Blue Cross & Blue Shield
Association, Choosingwisely.org and Choosingwiselycana-
da.org, and the Trip Database. Additional citations were
identified by (1) contacting experts in implementation sci-
ence; (2) using the PubMed “related articles” function; and
(3) hand-searching bibliographies from important im-
plementation science/adoption of innovations text-
books [9, 15, 16], and reference lists of included
citations. Reference management was performed in
EndNote (version X7, Thomson Reuters).
Citation selection
Prior to the screening of titles and abstracts, the cit-
ation screening form was calibrated by three team
members (DJN, KJM, JKH) independently with a ran-
dom sample of 50 citations. Once consistent citation
selection was achieved (kappa ≥ 0.8) [17], all citations
were screened for inclusion independently and in dupli-
cate by three reviewers through a two-stage process. Dur-
ing level-one screening, titles and abstracts were reviewed
to determine citations that met the inclusion/exclusion
criteria. The full text of any citation classified as “include”
or “unclear” was reviewed to determine whether it met
study inclusion criteria (level-two screening). Eligibility
disagreements were resolved by consensus, or arbitration
by a third reviewer. Agreement between reviewers at all
stages of citation selection was quantified using the kappa
statistic [17].
Data extraction and synthesis
Three reviewers independently extracted data from all
included citations using a pre-designed electronic form
that was pilot tested using a random sample of 10 cita-
tions. Once data were consistently abstracted (kappa ≥
0.8) [17], reviewers proceeded with full data extraction.
Extracted data pertained to (1) the citation (e.g., ori-
ginal research, non-original research, website); (2) the
term(s) used to refer to de-adoption (e.g., discontinu-
ance, medical reversal, rejection); (3) characteristics of
the target condition(s) or clinical practice(s) (e.g., use of
nesiritide in acute decompensated heart failure [18]);
(4) characteristics of evidence suggesting de-adoption
(e.g., original research versus non-original research); (5)
whether barriers and facilitators to de-adoption were
reported; and (6) whether conceptual frameworks to pro-
mote low-value practice de-adoption were used/cited.
Independently, and in duplicate, reviewers mapped
the abstracted data onto the proposed conceptual
framework. Articles were summarized using counts,
proportions, mean (standard deviation), or median (in-
ter-quartile range, IQR) where appropriate. Data were
managed and analyzed using Stata version 13.1 (Stata
Corp, College Station, TX, USA).
Results
The electronic database and gray literature searches iden-
tified 26,557 unique citations (Fig. 1) that were screened
for inclusion, from which 110 full text citations were re-
trieved for further assessment. An additional 51 articles
were identified through review of bibliographies, and
consultation with knowledge translation experts. From
these 161 full text citations, 109 were included in the
final review. The most common reason citations were
excluded after full text review was owing to an explicit
focus on the adoption and/or appropriateness of clin-
ical practices (n = 25).
Description of the included citations
A description of the included citations is provided in
Table 2. Most citations were original research studies
(65 %), with the majority being either quasi-experimental
(28 %) or cohort studies (14 %). Among the non-original
citations, most were editorials or letters to the editor
(19 %), or narrative reviews (15 %). Most articles originated
in North America (60 %) with the USA representing the
most common country (47 % of all articles). The majority
of articles were published from 2010 onwards (59 %), with
very few published prior to 2000 (3 %). Most articles de-
scribed the de-adoption of therapeutic interventions
(62 %), with comparatively fewer describing the de-
adoption of diagnostic interventions (30 %). The ran-
domized clinical trial was most frequently cited
(41 %) as the level of evidence that should trigger de-
adoption, and most articles cited risk of harm (73 %),
and/or lack of efficacy (63 %) as the reason practices
should be de-adopted. Among the articles that re-
ported the original reason for clinical practice adop-
tion (n = 16, 15 %), most (n = 10, 63 %) cited
observational research (case series and cohort studies)
Table 1 Proposed framework for conceptualizing de-adoption
Phase of de-adoption Operational definition
Identify low-value clinical practices Ascertain which clinical practices are of low value
Facilitate the de-adoption process Reduce the use of low-value clinical practices
Evaluate de-adoption outcomes Evaluate the outcomes of a strategy of de-adoption
Sustain de-adoption Prevent resurgence in use of low-value practices after their initial de-adoption
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as the evidence that shaped adoption. A detailed, ref-
erenced bibliography of the citations is provided in
Additional file 1: Table S1.
De-adoption terminology
We identified 43 unique terms representative of the process
of de-adoption (Table 3). The majority of citations (65 %)
referred to de-adoption using more than one term, and
among these the median (IQR) number of terms per
citation was 3 (2–3). Disinvest* was the most frequently
cited term (39 % of included citations). Other com-
monly cited terms included decrease use (24 %), discon-
tinu* (16 %), abandon* (16 %), reassess* (14 %), obsole*
(12 %), medical reversal (11 %), and contradict* (10 %).
Terms such as de-implement* and de-adopt* were in-
frequently cited (4 % and 3 %, respectively). A term rep-
resentative of the process of de-adoption was found in
the title or abstract of 86 % of citations and most fre-
quently included disinvest* (31 %), decrease use (12 %),
reassess* (7 %), withdraw* (7 %), medical reversal (6 %),
discontinu* (6 %), and obsole* (6 %). Each of the 43
unique terms was mapped onto our conceptual frame-
work. The majority of terms (n = 22, 51 %) referred to
facilitating the de-adoption process. Seventeen terms
(40 %) mapped to more than one category within the
conceptual framework, with the most common cross-
classification being facilitate de-adoption and sustain
de-adoption (13/17, 76 %).
Barriers and facilitators to de-adoption
Barriers and facilitators to de-adoption were cited
within 51 and 48 of the included citations respectively.
The bulk of articles citing barriers to or facilitators of
de-adoption were original research (Fig. 2).
Mapping citations to the de-adoption conceptual framework
Articles frequently mapped to more than one category
within our conceptual framework (Fig. 3). The primary
focus among included citations was evaluating de-
adoption outcomes (50 %), identifying low-value practices
(47 %), and facilitating the de-adoption process (40 %).
Two articles (2 %) discussed sustaining de-adoption. Most
articles whose focus was on evaluating de-adoption out-
comes were original research (80 %), whereas the majority
of articles that discussed identifying low-value practices
were non-original research (63 %).
Frameworks for the de-adoption of low-value clinical
practices were provided in 11 citations (Table 4), of
which half were derived from original research (n = 5,
45 %). Two citations documented clinical application of
their framework [19, 20]. Seven citations described
frameworks for identifying and prioritizing candidate
low-value practices, and nine citations described frame-
works for facilitating the de-adoption process. Among
citations that described a framework for identifying low-
value practices, common mechanisms included consult-
ation with clinical stakeholders, monitoring for new
scientific evidence, examining for practices with large
Fig. 1 Details of the article selection process. CADTH Canadian Agency for Drugs and Technologies in Health, KT Knowledge Translation
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between-provider variation, and/or embedding the no-
tion of health technology reassessment within the life
cycle of any given practice. Commonly proposed criteria
for prioritizing the de-adoption of low-value practices
included the availability of evidence that a candidate
practice is ineffective or harmful, the safety of the low-
value practice (i.e., harmful practices prioritized ahead of
those that are simply ineffective), potential health and
cost impact of de-adoption, and availability of alternative
practices. Among citations that described frameworks
for facilitating the de-adoption process, common mecha-
nisms included restructuring of funding associated with
the given practice, changes to local and/or regional pol-
icies, and more consistent integration of health technol-
ogy reassessment within existing health technology
assessment programs.
Lists of low-value practices were provided by eight cita-
tions (Table 5). Searches of the published literature were
the most frequently employed means of identifying low-
value practices (n = 7 citations, 88 %); however, the
sources searched and the approach to defining a low-value
practice varied by citation. Evidence was combined with
stakeholder engagement to identify low-value practices in
three citations [8, 21, 22], and one citation identified low-
value practices as those shown to have high variability in
rates of use between providers [23]. Among the seven cita-
tions that used the published literature to identify low-
value practices, the prevalence of low-value practices
ranged from 16 % [24] to 46 % [5], with two studies each
identifying more than 100 low-value practices [7, 8].
The impact of de-adoption efforts was evaluated and
reported in 39 original research citations (Table 6). Most
Table 2 Characteristics of included citations











Original research 71 (65)
Quasi-experimentalc 30 (28)
Cohort studyb 15 (14)
Mixed methods 8 (7)
Qualitative 4 (4)
Predictive modeling 3 (3)
Knowledge synthesis 3 (3)
Consensus method 3 (3)
Randomized clinical trial 1 (1)
Otherd 6 (6)
Non-original research 38 (35)
Editorial, letter to the editor, news item, other 21 (19)
Narrative review 16 (15)
Guideline 1 (1)
Focus of article
Identify low-value practices 51 (47)
Facilitate the de-adoption process 44 (40)
Evaluate de-adoption outcomes 54 (50)




Device or surgical procedure 16 (15)




Physiologic measurement 4 (4)
Diagnostic imaging 3 (3)
Screening program 1 (1)
Diagnostic tests not otherwise specified 12 (13)
Evidence to promote de-adoptionf
Randomized clinical trial 45 (41)
Knowledge synthesis 14 (13)
Table 2 Characteristics of included citations (Continued)
Clinical practice guideline 6 (5)
Cohort study 4 (4)
Quasi-experimentalc 2 (2)
Expert consensus 2 (2)
Reasons for de-adoptiong
Harm 80 (73)
Lack of efficacy 69 (63)
Not cost-effective 37 (34)
Percentages within each characteristic may not always total to 100 due to
rounding error, and/or redundancy within citations (e.g., a citation may have
more than one country of origin)
aNorth American countries: Canada, USA; European countries: UK, Belgium,
Denmark, France, Greece, Italy, Netherlands, Spain; Australian countries:
Australia, New Zealand
bIncludes six studies wherein the study population was a cohort of articles
identified through searches of the electronic literature
cIncludes interrupted time series, and before-and-after studies
dIncludes two surveys, one report on stakeholder engagement, one simulation
eType of intervention not reported in 32 studies
fNot reported in 46 studies (52 %)
gNot reported in 11 studies
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Table 3 De-adoption terms (n = 43) and frequency of their use within included citations
Terma Number (%) of
109 citationsb
Number (%) of citations






Disinvest* 42 (39) 34 (31) Facilitate de-adoption [7, 8, 19, 20, 23, 42, 46–81]
Sustain de-adoption
Decrease use 26 (24) 13 (12) Facilitate de-adoption [8, 26–28, 31, 33, 35, 37, 80, 82–99]
Evaluate de-adoption outcomes
Discontinu* 17 (16) 7 (6) Facilitate de-adoption [8, 18, 20, 23, 25, 28, 51, 56, 61,
63, 91, 94, 96, 100–103]
Evaluate de-adoption outcomes
Abandon* 17 (16) 4 (4) Sustain de-adoption [31, 54, 58, 63, 65, 84, 86, 97,
98, 100, 101, 103–108]
Reassess* 15 (14) 8 (7) Identify low-value practices [8, 18, 23, 46, 52, 58, 59, 68, 71,
80, 102, 108–111]
Obsole* 13 (12) 6 (6) Identify low-value practices [19, 20, 49, 55, 57, 58, 68, 73, 76,
80, 108, 109, 112]
Medical reversal 12 (11) 7 (6) Identify low-value practices [4, 5, 7, 61, 83, 85, 107, 113–117]
Contradict 11 (10) 3 (3) Identify low-value practices [5, 7, 24, 54, 65, 68, 85, 86, 104, 118, 119]
Re-invest 9 (8) 0 (0) Sustain de-adoption [8, 52, 54, 55, 68, 71, 73, 78, 80]
Withdraw* 8 (7) 8 (7) Facilitate de-adoption [29–36]
Sustain de-adoption
Reduc* 8 (7) 1 (1) Evaluate de-adoption outcomes [31, 32, 34–36, 120, 121]
Decline in use 7 (6) 0 (0) Evaluate de-adoption outcomes [96, 98, 99, 103, 120, 122, 123]
Health technology reassessment 5 (5) 4 (4) Identify low-value practices [52, 58, 59, 71, 110]
Change in use 4 (4) 2 (2) Evaluate de-adoption outcome [32, 118, 121, 124]
De-implement* 4 (4) 2 (2) Facilitate de-adoption [50, 65, 125, 126]
De-list 4 (4) 0 (0) Facilitate de-adoption [57, 68, 80, 109]
Sustain de-adoption
Low value practice/intervention 4 (4) 2 (2) Identify low-value practices [7, 70, 78, 127]
Change in practice 3 (3) 1 (1) Evaluate de-adoption outcome [36, 103, 118]
De-adopt* 3 (3) 2 (2) Facilitate de-adoption [18, 100, 128]
Evaluate de-adoption outcomes
De-commission 3 (3) 1 (1) Facilitate de-adoption [68, 72, 80]
Sustain de-adoption
Do not do 3 (3) 1 (1) Facilitate de-adoption [21, 22, 56]
Reallocation 3 (3) 0 (0) Sustain de-adoption [58, 73, 109]
Remov* 3 (3) 0 (0) Facilitate de-adoption [29, 33, 37]
Sustain de-adoption
Replace 3 (3) 0 (0) Facilitate de-adoption [4, 111, 114]
Sustain de-adoption
Refute 3 (3) 1 (1) Identify low-value practices [24, 83, 104]
Over use 3 (3) 0 (0) Identify low-value practices [37, 127, 129]
Stop* 3 (3) 1 (1) Facilitate de-adoption [35, 77, 124]
Inappropriate use 2 (2) 1 (1) Identify low-value practices [112, 129]
Relinquish* 2 (2) 1 (1) Facilitate de-adoption [97, 98]
Sustain de-adoption
Ineffective 2 (2) 1 (1) Identify low-value practices [19, 29]
Misuse 1 (1) 0 (0) Identify low-value practices [127]
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studies used interrupted time series methodology (n =
21, 54 %) and obtained data from large administrative
databases or clinical registries (n = 30, 76 %). The most
common target conditions were cardiovascular disease
(n = 11, 28 %), arthritides (n = 8, 21 %), and menopause
(n = 7, 18 %). All but one of the practices (pulmonary ar-
tery catheter) examined were therapeutic interventions.
The most frequently examined therapies included cyclo-
oxygenase-2 (COX-2) inhibitors and other non-steroidal
anti-inflammatory drugs (NSAIDs) (n = 8, 21 %), hormone
replacement therapy (n = 7, 18 %), and percutaneous cor-
onary intervention (n = 3, 8 %). Thirteen studies re-
ported on de-adoption efforts that followed an active
change intervention, all of which demonstrated reduc-
tions in the target low-value practice [25–37]. The
most common intervention was withdrawal of a low-
value drug from the market (n = 9, 23 %). Other
active change interventions commonly included an
education component targeted at patients and/or pro-
viders. Of the 26 studies that did not report on the
effects of an active change intervention, 23 (88 %)
demonstrated reductions in the target practice. Of the
27 and 11 studies that examined de-adoption efforts
for harmful or ineffective practices, respectively, 25
(92 %) and 9 (81 %) demonstrated reductions in the
target practice.
Discussion
De-adoption of low-value clinical practices is essential to
improve healthcare quality and create a sustainable
healthcare system. To our knowledge this is the first
knowledge synthesis to comprehensively examine the de-
adoption of low-value clinical practices. We identified 109
citations, most of which were published within the last five
years, and concentrated on evaluating changes in practice
that occurred following the publication of evidence for
medical reversal. We identified 43 terms used to refer to
the process of de-adoption, with disinvest being the most
frequently cited term. We also identified 13 frameworks
that conceptualize individual components of the de-
adoption process, and from these frameworks propose a
model for de-adoption (Fig. 4). These results provide
foundations for guiding the de-adoption of ineffective and
harmful clinical practices from patient care as well as
directing future research.
The first major finding from our study pertains to the
diverse list of terms used to refer to de-adoption with no
clearly established taxonomy. The implication of this is
that communication is impaired, which may impact
“branding” of de-adoption and efficient searching for
relevant literature. Furthermore, it is unclear how differ-
ent concepts and initiatives such as “less is more” [38],
reducing research waste [39], and Choosing Wisely [40]
Table 3 De-adoption terms (n = 43) and frequency of their use within included citations (Continued)
Re-appraisal 1 (1) 0 (0) Identify low-value practices [79]
Re-prioritization 1 (1) 0 (0) Sustain de-adoption [79]
Substitutional re-investment 1 (1) 0 (0) Facilitate de-adoption [79]
Sustain de-adoption
Evidence-based reassessment 1 (1) 0 (0) Identify low-value practices [79]
Clinical redesign 1 (1) 0 (0) Facilitate de-adoption [79]
Disadoption 1 (1) 0 (0) Facilitate de-adoption [101]
Defunding 1 (1) 0 (0) Facilitate de-adoption [57]
Sustain de-adoption
Resource release 1 (1) 0 (0) Facilitate de-adoption [57]
Sustain de-adoption
Withdrawing from a service
and redeploying resources
1 (1) 0 (0) Facilitate de-adoption [57]
Sustain de-adoption
Redeploy 1 (1) 1 (1) Facilitate de-adoption [68]
Sustain de-adoption
Reversal 1 (1) 0 (0) Identify low-value practices [96]
Facilitate de-adoption
Sustain de-adoption
Drop in use 1 (1) 0 (0) Facilitate de-adoption [31]
Evaluate de-adoption
a*wildcard notation denotes multiple endings for a given term
bPercentages do not total 100 owing to the appearance of multiple terms within individual citations
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are related. Conversely, knowledge translation and im-
plementation science are increasingly recognized terms
in healthcare research, facilitating understanding and
communication of the related concepts. Terms such as
de-adoption and de-implementation that have a more
general connotation, and are natural antonyms of adop-
tion and implementation, ought to be used as terms that
brand the process of reducing or removing low-value
clinical practices. Other terms, such as disinvest, de-
scribe specific elements of the de-adoption process and
are not ideal candidates to brand this process. Interest-
ingly, de-adoption and de-implementation were infre-
quently cited within the included citations, whereas
disinvest was the most commonly cited term. Given this
Fig. 2 Distribution of articles citing barriers to and facilitators of de-adoption according to type of research
Fig. 3 Distribution of articles according to classification within the conceptual framework and type of research
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Table 4 Frameworks proposed to guide the de-adoption of low-value practices




Elshaug et al. 2009 [109] Discussion paper prepared by Canadian
Agency for Drugs and Technologies in
Health Health Technology Strategy
Policy Forum
Identify low-value practices Criteria for identifying existing, potentially
non-cost-effective practices as candidates
for assessment
No
Criteria to inform the prioritization of candidates
for detailed review after identification
Facilitate the de-adoption process Funding approaches to facilitating reduction in
non-cost-effective practices
No
Joshi et al. 2009 [80] Narrative review Identify low-value practices HTR approach to identifying candidate technologies No
Ibargoyen-Roteta et al. 2010 [55] Guideline Identify of low-value practices GuNFT: Hospital and patient-level criteria for not
funding technologies
No
Facilitate the de-adoption process Barriers and mechanisms to remove funding from
existing technologies
No
Mortimer 2010 [68] Narrative review Facilitate the de-adoption process Proposed re-orientation of traditional PBMA model
to target strategies of disinvestment
Not with the re-oriented
PBMA model as outlined
by the authors
Donaldson et al. 2010 [72] Narrative review Facilitate the de-adoption process Describes the use of PBMA to promote rational
disinvestment
Not according to the model
outlined by the authors
Gerdvilaite and Nachtnebel 2011 [57] Systematic review Identify of low-value practices Authors cite criteria proposed by Elshaug et al. [109],
Joshi et al. [80], Ibargoyen-Roteta et al. [55], and
criteria proposed by National Institute for Health
and Care Excellence
No
Overlapping criteria include new evidence, cost
effectiveness, safety, and available alternatives
Facilitate the de-adoption process As described above for Ibargoyen-Roteta et al. [55] No
Levin 2011 [20] Conference presentation Identify of low-value practices Ontario’s Evidence-based Analyses to Manage
Technology Adoption and Obsolescence:
Mega-analysis Evidence Based Analyses of
technologies around disease conditions;
prioritized by effectiveness and cost-effectiveness;
criteria for identifying practices unclear
Yes
Facilitate the de-adoption process Mechanism for facilitating de-adoption appears to be
based on funding effective technologies, and not
funding ineffective technologies
Yes
Leggett et al. 2012 [58] Systematic review Identify of low-value practices;
Facilitate the de-adoption process
1.GuNFT as outlined above No















Table 4 Frameworks proposed to guide the de-adoption of low-value practices (Continued)
Watt et al. 2012 [46] Mixed methods Facilitate the de-adoption process Two technologies (assisted reproductive technology
and vitamin B12/folate pathology tests) used as





3. Policy deliberation and analysis; Process evaluation
Henshall and Schuller 2012 [52] Qualitative Identify of low-value practices Identification and prioritization approaches include
clinical stakeholder involvement, monitoring new
evidence, use of data to identify practices with
high variability and/or cost, inclusion of HTR
within life-cycle of any technology
No




1. Health technology assessment framework
2. Program budgeting and marginal analysis
3. Accountability for reasonableness and
quality improvement theory













Table 5 Original research citations that identified lists of low-value clinical practices
Citation Stakeholder engagement Single clinical area of focus Methodology Results
Ioannidis 2005 [24] No No Broad literature search (1990–2003) for highly cited clinical
research studies published in three major clinical journalsa
or medical specialty journals with an impact factor >7.0
7 of 45 (16 %) highly cited studies
claiming effectiveness eventually
contradicted by replication research
Supplemental, tailored searches to determine if each
highly cited study had been replicated
7 other replication studies (16 %)
found effect size not as large as in
original study
Comparison of direction of results between replicated
and original highly cited study
Prasad et al. 2011 [5] No No Review of all “original articles” published in New England
Journal of Medicine in 2009
35 of 124 (28 %) articles examined
an existing medical practice
Articles classified according to whether the practice
examined was new or already in place, and
whether the results were positive or negative
for the primary endpoint
16 of 35 (46 %) articles examining
an existing practice demonstrated
medical reversalb
Elshaug et al. 2012 [8] Comprehensive Management
Framework for Australia’s
Medicare Benefits Schedule
No Environmental scanning approach triangulating data
from broad PubMed search (2000–2010), targeted
searches within select databases (e.g., Cochrane
library), and opportunistic sampling among
clinical and non-clinical stakeholders
156 potentially ineffective or unsafe
practices identified from 5,209
screened articles
Excluded pharmaceuticals
Choosing Wisely 2012 [21] Yes Yes, specialty specific
recommendations
Varied by specialty society but generally included one
or more of literature search, expert opinion, and/or
a modified Delphi process
67 specialty specific Top 5 ‘do
not do’ lists
Garner et al. 2013 [70] NICE No Present results from the first 6 months of the
Cochrane Quality and Productivity project to
identify low-value practices
28 of 65 (43 %) reviews published
over a 6-month period identified
potentially low-value practices
Routine scanning of “implications for practice” section in
new or updated Cochrane reviews to identify those
wherein the author concluded an intervention is
ineffective/harmful or should be confined to
use within a research context
Most reviews cited a lack of
randomized evidence of
effectiveness, rather than robust
evidence of lack of effectiveness
Each review is examined to ensure it meets Cochrane
Quality and Productivity criteria (potential impact on
quality, safety, patient/provider experience, and
potential for cash-releasing savings) for recommendation
as a potential “disinvestment” candidate
To date the NICE Health Technology
Appraisal Program has generated
1,347 ‘do not do’ recommendations [130]
Hollingworth et al. 2013 [23] No Yes, interventional procedures Used UK Hospital Episode Statistics to identify inpatient
interventional procedures with high variation in rates
of use between PCTs in England
Substantial inter-procedure, inter-PCT
variation in procedure rates













Table 5 Original research citations that identified lists of low-value clinical practices (Continued)
Prasad et al. 2013 [7] No No Review of all original research articles published in
New England Journal of Medicine from 2001 to 2010
363 of 1,344 (27 %) articles re-examined
an established practice
Articles classified according to whether the
practice examined was new or already in
place, and whether the results were positive
or negative for the primary endpoint
146 of 363 (40 %) articles re-examining
an existing practice demonstrated
evidence of reversal
Articles further classified as replacement, back
to the drawing board, reversal, or reaffirmationd
Choosing Wisely
Canada 2014 [22]
Yes Yes, specialty specific
recommendations
Varied by specialty society but generally
included one or more of literature search,
expert opinion, and/or a modified Delphi process
61 recommendations across 18
medical and surgical specialties
aMajor clinical journals included New England Journal of Medicine, Journal of the American Medical Association, and The Lancet
bMedical reversal occurs when a new study—superior to predecessors because of better design, increased power, or more appropriate controls—contradicts current clinical practice [5]
cConference abstract limited availability of data from this study
dReplacement = new practice surpasses older standard of care; back to the drawing board = new practice fails to surpass standard of care; reversal = current practice inferior to a lesser or prior standard;
reaffirmation = existing practice superior to a lesser or prior standard













Table 6 Original research citations that evaluated the de-adoption of low-value clinical practicesa
Citation Study
design




















Arthritides COX-2 inhibitors RCT Harmful Yes Safety concerns for rofecoxib
interpreted as class effect
Thiebaud et al.
2006 [31]
Cohort study Arthritides COX-2 inhibitors RCT Harmful Yes Greater decrease in COX-2 inhibitor
use among patients with greater





Arthritides COX-2 inhibitors RCT Harmful Yes Safety concerns for rofecoxib
interpreted as class effect;
prescription of non-selective
NSAIDs increased
Sun et al. 2007 [33] Interrupted time
series
Arthritides COX-2 inhibitors RCT Harmful Yes Significant increases in non-selective
NSAID use after withdrawal of
rofecoxib and valdecoxib
Setakis et al. 2008 [34] Before-and-after Arthritides COX-2 inhibitors RCT Harmful Yes After withdrawal of rofecoxib,
remaining use of COX-2 inhibitors
did not concentrate in patients
with high gastrointestinal risk
and low cardiovascular risk
Sukel et al. 2008 [35] Before-and-after Arthritides COX-2 inhibitors RCT Harmful Yes Safety concerns for rofecoxib
interpreted as class effect
Hsiao et al. 2009 [36] Cohort Arthritides COX-2 inhibitors RCT Harmful Yes Safety concerns for rofecoxib







Case–control study Harmful Yes No change in practice after reports of
adverse events. Market withdrawal of
drug required to change practice





Not reported Yes No recrudescence of symptomatology
associated with original PPI prescription
after its discontinuation
Roumie et al. 2004 [25] Interrupted
time series
Post-menopausal women HRT RCT Harmful Yes Greater rate of discontinuation of
HRT after tailored de-adoption
intervention compared to media
release of results of WHI study
Kulawik et al. 2009 [28] Before-and-after End-stage renal disease Use of tunnelled
hemodialysis catheters








Yes Involvement of medical leader














Table 6 Original research citations that evaluated the de-adoption of low-value clinical practicesa (Continued)
Sindby et al. 2011 [26] Before-and-after Coronary artery
bypass surgery
Blood transfusions Not reported Not reported Yes Not reported (conference abstract)
No intervention used to facilitate de-adoptionc






HRT RCT Harmful Yes Unable to determine if decline in





HRT RCT Harmful Yes Factors associated with stopping
HRT included older age, use of
combined HRT, longer duration
of HRT




HRT RCT Harmful Yes Greater decrease in HRT use after
WHI study compared to Heart
and Estrogen/progestin
Replacement Study












HRT RCT Harmful Yes Substantial decline in promotional






HRT RCT Harmful Yes Factors associated with reduction
in use of HRT included higher










Harmful Yes No difference in calcium channel
blocker discontinuation according
to physician specialty




Hypertension Short acting calcium
channel blockers








Hypertension Alpha-blockers RCT Harmful Yes Substantial decrease in office
promotion expenditures for
alpha-blockers following
publication of ALLHAT trial
Xie et al. 2005 [95] Interrupted
time series
Hypertension Alpha-blockers RCT Harmful Yes Decrease in alpha-blockers








Nesiritide Systematic review Harmful Yes Decrease in nesiritide use associated
with increased use of inotropes
Atwater et al.
2009 [90]
Before-and-after Coronary artery disease PCI RCT Lack of efficacy Yes Decrease in PCI and increase


















Before-and-after Coronary artery disease PCI RCT Lack of efficacy Yes PCI use decreased after COURAGE
trial, however considerable number
of patients with stable angina
continued to receive PCI
Deyell et al. 2011 [89] Interrupted time
series
Coronary artery disease PCI RCT Lack of efficacy No No change in PCI after OAT





Coronary artery disease PCI RCT Lack of efficacy Yes Decrease in PCI use was sustained






Critical illness PAC RCT; Systematic
review
Lack of efficacy Yes PAC use began to decline after
publication of large observational
study (before publication of
any RCTs)
Koo et al. 2011 [87] Interrupted
time series
Critical illness PAC RCT; Systematic
review
Lack of efficacy Yes Examined patient, physician, and
unit-level predictors of PAC use
Gershengorn and
Wunsch 2013 [128]
Cohort Critical illness PAC RCT; Systematic
review
Lack of efficacy Yes Surgical patients continue to
have high likelihood of PAC use
Murphy et al.
2013 [92]
Cohort Critical illness Blood transfusions RCT Harmful Yes (higher
volume
hospitals only)
Likelihood of receiving blood
transfusion after publication of







IPPB RCT Lack of efficacy Yes Hospital-level traits and models
of funding technologies were





Cisapride Case series; Warning
letter from Food and
Drug Administration
Harmful No Cisapride use not effected by







Breast cancer High dose chemotherapy/
Hematopoietic cell
transplants
RCT Lack of efficacy
and harmful
Yes No association between hospital
teaching status and participation
in clinical trials, and decline in













No “Do not do” recommendation
reminders had no association






Cohort Prostate cancer RRP Cohort study Not reported Yes Decrease in RRP was associated














Table 6 Original research citations that evaluated the de-adoption of low-value clinical practicesa (Continued)
Luetmer and
Kallmes 2011 [88]
Before-and-after Vertebral fracture Vertebroplasty RCT Lack of efficacy Yes Referrals for vertebroplasty
decreased, however proportion






Diabetes mellitus Rosiglitazone Systematic review
Cohort study
Harmful Yes No significant change in markers
of glycemic control after
discontinuation of rosiglitazone
aFive citations excluded from this table discussed, but did not actually evaluate the outcome of a de-adoption process [52, 59, 106, 123, 125]
bCitations that employed a de-adoption intervention included:
- Ross-Degnan et al. [29]: Market withdrawal of Zomepirac
- Williams et al. [30], Thiebud et al. [31], Barozzi and Tett [32], Sun et al. [33], Setakis et al. [34], Sukel et al. [35], Hsiao et al. [36]: Market withdrawal of rofecoxib
- Stafford and Radley [37]: Market withdrawal of fenfluramine and dexfenfluramine
- Krol et al. [27]: Information leaflet with recommendations for reducing inappropriate PPI use sent to patients from general practice clinics
- Roumie et al. [25]: Three-part intervention consisting of patient and provider education component and provider care component
- Kulawik et al.,[28]: Catheter reduction toolkit (education on types of vascular access) employed in facilities with high catheter utilization rates
- Sindby et al. [26]: Provider education, audit and feedback, and hospital-level guideline changes
cAny observed de-adoption reflects the effect of passive diffusion of evidence of a practice’s ineffectiveness or harm
COX-2 cyclo-oxygenase-2, HRT hormone replacement therapy, IPPB intermittent positive pressure breathing, NSAIDs non-steroidal anti-inflammatory drugs, PAC pulmonary artery catheter, PCI percutaneous coronary













lack of clarity with regard to de-adoption terminology,
there is an urgent need to develop a taxonomy of terms.
Using the proposed conceptual framework (Table 1),
themes common to the frameworks identified in the
scoping review (Table 4), and the Knowledge-to-Action
framework [41], we derived the second major result
from this study, a synthesis framework for facilitating
de-adoption (Fig. 4). At the heart of this framework is
the identification and prioritization of low-value prac-
tices. The identification process involves determining the
low-value practice(s) and selection of the knowledge unit
that defines a practice as low-value (i.e., randomized
clinical trial, systematic review, and/or clinical practice
guideline). With regard to prioritization when there is
more than one low-value practice identified, current lit-
erature suggests prioritizing based on strength of evi-
dence supporting lack of efficacy, safety of the low-value
practice (i.e., harmful practices eliminated first), poten-
tial health and cost impact of de-adoption, and availabil-
ity of alternative practices. To permit more of an
integrated de-adoption process, and thus improve the
probability of success, we suggest stakeholder engage-
ment take place concomitant with practice identification
and prioritization. The de-adoption process is then
envisioned to follow a similar action cycle as in the
original Knowledge-to-Action cycle [41]. However,
given the anticipated challenges associated with dis-
continuing established clinical practices [42], the ana-
lysis of barriers and facilitators will require a greater
in-depth exploration of both scientific (e.g., presence
and quality of evidence supporting de-adoption) and
non-scientific (e.g., historical, political, social, and
economic factors) barriers to de-adoption [43]. In
addition, the intervention that guides de-adoption will
likely need to be more closely integrated into clinical
care pathways compared to that for adoption, with
policy changes and/or changes to funding models pre-
dicted to have the greatest likelihood of facilitating
de-adoption. Implementation of the intervention will
need to be evaluated, and outcomes such as low-
value practice use, costs, and potential harms
assessed. Finally, any de-adoption intervention should
include a sustainability plan; else it is highly likely
that healthcare providers will (knowingly or unknow-
ingly) revert to using the practice to which they have
become habituated [44].
Fig. 4 Synthesis model for the process of de-adoption. a Identification of low-value practices includes the process of reviewing and selecting
de-adoption knowledge. b Current literature suggests prioritizing based on safety of the low-value practice (i.e., harmful practices eliminated
first), potential health and cost impact of de-adoption, and availability of alternative practices
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The third important result from this review is the identi-
fication of key questions that require additional research to
advance the science of de-adoption. For example, there are
multiple factors that likely determine when a practice
should be de-adopted (e.g., nature of the intervention, lack
of effectiveness or degree of harm, nature of the evidence)
but the role of each factor and the interplay among them
that ultimately determines when to de-adopt is not clear.
In addition, what do we do with clinical practices that are
ineffective for a broad population, but may be effective in a
small subgroup that is difficult to study? To answer these
and other questions we need additional knowledge synthe-
ses that establish a taxonomy of de-adoption terminology,
summarize barriers and facilitators to de-adoption, and
quantify the impact of past examples of de-adoption. We
also need empirical research to examine optimal strategies
for identifying candidate low-value practices, and to deter-
mine which de-adoption strategies are likely to have the
greatest impact. Furthermore, given existing fiscal climates
with limited resources, we also need to balance the need to
refine and prioritize the science of de-adoption with the
need to do the same for adopting new practices.
While we await this additional research, what can
healthcare decision-makers practically do with the existing
knowledge base? First, this review highlights that de-
adoption requires a multi-dimensional construct that is
far more complex than simply ceasing to provide a given
practice. Second, several studies have demonstrated that
de-adoption does occur in response to publication of new
evidence (Table 6), with the most consistent de-adoption
occurring in response to an active change intervention.
The intervention with the greatest likelihood of de-
adoption is market withdrawal of a harmful drug.
However, the real challenge lies in how to actively facili-
tate de-adoption when market withdrawal is not possible
(e.g., insulin [45]), or not clearly indicated (e.g., practices
that are simply ineffective). Interventions cited as having
the greatest likelihood of effecting de-adoption include
changes to policies, and/or restructuring of funding asso-
ciated with the low-value practice, the latter through strat-
egies of disinvestment, reinvestment, or defunding.
However, this scoping review did not identify any studies
that applied a strategy of disinvestment in response to evi-
dence for medical reversal. At this point, pending further
research, we suggest use of our proposed synthesis model
(Fig. 4) as a starting point for anyone interested in pro-
moting the de-adoption of low-value practices.
There are limitations to this review. First, our search
may have missed relevant articles due to the lack of
indexing terminology specific to de-adoption that for
practical reasons forced us to restrict the search to
English language articles published from 1990 onwards.
However, the majority of included citations were pub-
lished after 1999, and originated in high-income
countries, therefore it is unlikely that we missed any
broad concepts related to de-adoption. Second, grouping
articles and de-adoption terminology according to the
main categories in the conceptual framework, even
though completed in duplicate by independent re-
viewers, is partly subjective. Finally, we elected to con-
duct a scoping review in order to provide an inclusive
and broad description of what is known about de-
adoption and therefore are limited in our ability to
present granular details. Our work identifies opportun-
ity for future systematic reviews.
Conclusions
De-adoption of low-value clinical practices is essential to
improve healthcare quality and create a sustainable
healthcare system. We identified a large body of litera-
ture that describes current approaches, and challenges
to the de-adoption of low-value clinical practices. Our
results should promote future research in at least two
areas. First, knowledge syntheses are required to explore
areas wherein there is an abundance of literature, such
as establishing a taxonomy of de-adoption terminology,
summarizing barriers and facilitators to de-adoption,
and quantifying the impact of past examples of de-
adoption. Second, empirical research is required to
examine optimal strategies for identifying candidate low-
value practices, and to determine which de-adoption
strategies are likely to have the greatest impact. In the
meantime, we have developed a conceptual model that
providers and decision-makers can use to guide efforts
to de-adopt ineffective and harmful practices and de-
scribe examples of successful de-adoption that can be
used to inform efforts.
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